Literature DB >> 11865137

Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy.

R Borghi1, L Giliberto, A Assini, A Delacourte, G Perry, M A Smith, P Strocchi, D Zaccheo, M Tabaton.   

Abstract

BACKGROUND: Progressive supranuclear palsy (PSP) is characterized by a pure neurofibrillary tau pathology involving mainly basal ganglia and brainstem nuclei. In addition to a haplotype of the tau gene potentially favoring tau aggregation, lipoperoxidation has been shown to be associated with PSP tau pathology.
OBJECTIVE: To analyze cdk5/p35 complex, a kinase that regulates neurite outgrowth, as a potential cellular mechanism underlying tau phosphorylation in brain tissues from PSP and control cases and comparatively in cerebral cortex from subjects with AD.
METHODS: Cdk5/p35 protein levels and distribution were evaluated by immunoblotting and immunocytochemistry in brain regions from seven PSP, six AD, and seven control cases, with similar postmortem intervals.
RESULTS: Total cdk5 protein levels were significantly increased by more than threefold in PSP tissue and were augmented in PSP neurons, codistributed with tau immunoreactivity. P35, the regulatory subunit of cdk5, was degraded by postmortem proteolysis to the same extent in PSP, AD, and control tissues.
CONCLUSIONS: The proteolysis in vivo of p35, the regulatory subunit of the kinase, is not ascertainable because it is masked by its postmortem degradation. The study, however, indicates that in PSP, the alteration of cdk5 is different from that described in AD and suggests that the absence of amyloid beta protein deposition may account for the different pathways responsible for the same kinase activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11865137     DOI: 10.1212/wnl.58.4.589

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Cdk5 protein inhibition and Aβ42 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease.

Authors:  Katherine R Sadleir; Robert Vassar
Journal:  J Biol Chem       Date:  2012-01-05       Impact factor: 5.157

2.  Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice.

Authors:  Takashi Ishizawa; Narahiko Sahara; Koichi Ishiguro; Jay Kersh; Eileen McGowan; Jada Lewis; Michael Hutton; Dennis W Dickson; Shu-Hui Yen
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

Review 3.  Recent advances in our understanding of neurodegeneration.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

Review 4.  Discovery of compounds that will prevent tau pathology.

Authors:  Kenneth S Kosik; Jae Ahn; Ross Stein; Li-An Yeh
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

5.  Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons.

Authors:  Michel Cyr; Jean-Martin Beaulieu; Aki Laakso; Tatyana D Sotnikova; Wei-Dong Yao; Laura M Bohn; Raul R Gainetdinov; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-04       Impact factor: 11.205

Review 6.  An unusual member of the Cdk family: Cdk5.

Authors:  Fatema A Dhariwala; Medha S Rajadhyaksha
Journal:  Cell Mol Neurobiol       Date:  2008-01-08       Impact factor: 5.046

Review 7.  Frontrunner in Translation: Progressive Supranuclear Palsy.

Authors:  Ali Shoeibi; Nahid Olfati; Irene Litvan
Journal:  Front Neurol       Date:  2019-10-22       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.